InvestorsHub Logo
Followers 164
Posts 12802
Boards Moderated 1
Alias Born 01/26/2016

Re: AVII77 post# 56143

Sunday, 03/06/2016 10:56:42 PM

Sunday, March 06, 2016 10:56:42 PM

Post# of 693129
AVII77,

Ok, I understand post trial data analysis gets the boot. That is what happened to Stimuvax. I am talking about a prespecified and accounted for subset in this trial for which you yourself said there was a .03 spend left out to work with. You have guessed at how it is being used with regard to an endpoint change. Is there an alternative here with regard to mesenchymal patients that you haven't shared yet?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News